|
| Partnership |
| |
 |
axxonis has
acquired the Technology which guarantees axxonis to
receive and purchase exclusive patent rights
and know-how to certain products. |
|
Alfarma
s.r.o., Prague, Czech Republic |
|
Novosis,
Munich: for development of lisuride TTS
and GMP, manufacturer of clinical service
form. |
|
MDS,
Munich, for performing Phase I clinical
testing |
|
MDS,
Zurich, for Bioanalytics |
|
Kendle,
CRO, Munich for clinical development |
|
axxonis
has started a discovery research program
with scientists from the Academy of Sciences
in Prague, CZ and the Free University Berlin
to provide multiple drug candidates against
various drug targets to broaden our product
portfolio in the area of neurodegenerative
and other disorders. |
|
Leopold-Franzens-Universität
Innsbruck, Austria. Prof. Dr. W. Poewe,
Principal investigator, Lisuride TTS. |
|
Universität
Bochum, Prof. Dr. Przuntek. |
|
Ivax,
CR (formerly known as Galena), Opava, Cz:
producer of Lisuride |
|
IMEREM
GmbH, CRO, Nuernberg, Germany, for clinical
development |
|
Conventis
AG, CRO, Rostock, Germany |
|
Fisher
Clinical Services CH GmbH, Switzerland |
|
| |
Print:
|
|
|
